You are viewing a javascript disabled version of the site. Please enable JavaScript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer

Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.

Boolean operators
This OR that
This AND that
This NOT that
Must include "This" and "That"
This That
Must not include "That"
This -That
"This" is optional
This +That
Exact phrase "This That"
"This That"
(this AND that) OR (that AND other)

Wildcard searches using asterisks can be used: "pseu* cand*" will identify "pseudomembranous candidosis".

Go to chapter navigation
Figure c22/f001
Figure 22.1
‘Porphyrin’ photodynamic therapy uses the haem cycle. ALA, 5‐aminolaevulinic acid; CoA, co‐enzyme A; MAL, methyl aminolevulinate.
Figure c22/f005
Figure 22.5
Bowen disease on the lower leg (a) before and (b) 1 year after photodynamic therapy (PDT). Stasis change, oedema and xerosis were prominent and althou...
Figure c22/f009
Figure 22.9
Lesion preparation using a disposable ring curette.
Figure c22/f013
Figure 22.13
Photodynamic therapy to the lower leg using a red LED source.
Figure c22/f017
Figure 22.17
Expected residual erythema and crusting 1 week after photodynamic therapy.
Figure c22/f021
Figure 22.21
Positive patch tests confirming contact allergy to a proprietary preparation of 5‐aminolaevulinic acid (ALA). Contact allergy to both ALA and methyl a...
Figure c22/f002
Figure 22.2
Crimson red protoporphyrin IX fluorescence in a superficial basal cell carcinoma 3 h after methyl aminolevulinate application, showing the tumour spec...
Figure c22/f006
Figure 22.6
Superficial basal cell carcinoma on the back (a) before and (b) 1 year after photodynamic therapy. Note the excellent cosmetic outcome, with only the ...
Figure c22/f010
Figure 22.10
Pro‐drug application.
Figure c22/f014
Figure 22.14
Ambulatory photodynamic therapy. Irradiation is underway, as indicated by the red light emission from the portable inorganic LED source (Ambulight).
Figure c22/f018
Figure 22.18
Severe phototoxic reaction persisting 1 week after photodynamic therapy in a fair‐skinned subject with marked field change photodamage.
Figure c22/f003
Figure 22.3
Absorption spectrum of protoporphyrin IX.
Figure c22/f007
Figure 22.7
Photodynamic therapy (PDT) is ideal for multiple and/or large lesions and field change. This patient had extensive actinic keratosis, Bowen disease an...
Figure c22/f011
Figure 22.11
Pro‐drug occlusion under Tegaderm. An additional UV/visible light opaque dressing would also be applied if the lesion is on an exposed site.
Figure c22/f015
Figure 22.15
Daylight photodynamic therapy (PDT) allows field areas of superficial actinic keratosis on exposed sites to be treated in one session. This man had da...
Figure c22/f019
Figure 22.19
Urticaria at the treatment site immediately after photodynamic therapy.
Figure c22/f004
Figure 22.4
Field treatment of actinic keratoses on the forehead and temple (a) before and (b) 3 months after a single treatment of topical photodynamic therapy.
Figure c22/f008
Figure 22.8
Photodynamic therapy (PDT) is ideal for lower leg sites as the risk of poor healing and ulceration is reduced. This patient has lower leg oedema, stas...
Figure c22/f012
Figure 22.12
Mapping out the irradiation field to include a 5 mm rim of clinically uninvolved skin.
Figure c22/f016
Figure 22.16
Erythema and oedema immediately after photodynamic therapy.
Figure c22/f020
Figure 22.20
Dermatitis arising at the photodynamic therapy (PDT) treatment site in a patient who had received multiple treatments with topical PDT to field areas....